Study of FOLFIRI Plus Cetuximab Plus IMO-2055 in Patients With Colorectal Cancer
Status:
Terminated
Trial end date:
2011-08-01
Target enrollment:
Participant gender:
Summary
Open-label phase 1b trial. Study treatment will be administered in 3 week cycles.
There are two distinct parts in this study:
- Part 1: Dose escalation from IMO-2055
- Part 2: Once a recommended phase 2 dose is found additional tolerability and
pharmacodynamics will be explored